Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
1+ hour, 6+ min ago (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
2+ hour, 51+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
4+ hour, 43+ min ago (1584+ words) Daiichi Sankyo and AstraZeneca's Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo…...
Switch From Trava to PlexusDx: Evidence Gaps and What to Verify
11+ hour, 59+ min ago (1428+ words) Shop all 5 Weight Loss programs → Compare GLP-1 providers → Start Weight Loss intake → Shop all 5 Longevity programs → Start Longevity intake → GLP-1 & Peptide Pathways Food Sensitivity & Allergies Diet & Weight Loss Cognition and Brain Health Genetic Test Stress and Mental Health Genetic Test…...
Phase III MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for Small-Cell Lung Cancer
17+ hour, 34+ min ago (171+ words) Sep 13, 2026, 08:54 ET For decades, PCI has been used after initial therapy for SCLC because studies conducted before routine MRI demonstrated that it reduced brain metastases and improved overall survival. MAVERICK was designed to determine whether modern MRI surveillance could allow…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. [IMAGE] | EurekAlert! Science News Releases
1+ day, 38+ min ago (74+ words) dijo la profesora Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China.
1+ day, 2+ hour ago (72+ words) EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. More on this News Release Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves…...
WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial
15+ hour, 26+ min ago (16+ words) FirstWord Pharma...
The week in pharma: action, reaction and insight – week to September 11, 2026
17+ hour, 21+ min ago (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...
Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
17+ hour, 31+ min ago (164+ words) Sep 13, 2026, 08:57 ET Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved progression-free survival and response rates Relapsed SCLC remains a highly aggressive disease with limited effective treatment options and poor outcomes following first-line immunotherapy and platinum-based…...